Tacrolimus

證據等級: L5

預測適應症: 3 個

Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis

One-Sentence Summary

Tacrolimus (topical) was originally developed for atopic dermatitis, where it works as a non-steroidal calcineurin inhibitor. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 clinical trials and 20 publications currently supporting this direction, including a Phase 3 and a Phase 4 completed trial specifically designed for facial seborrheic dermatitis.

Quick Overview

Item	Content
Original Indication	Atopic Dermatitis (topical formulation; per repurposing rationale — structured `original_indications` field itself is empty in the evidence pack)
Predicted New Indication	Seborrheic Dermatitis
TxGNN Prediction Score	99.26%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action (MOA) data is currently a documented data gap (DG002, High severity). However, the evidence pack's repurposing rationale contains established mechanistic reasoning: tacrolimus is a calcineurin inhibitor. It suppresses T-cell activation and downstream inflammatory cytokine release, which is the basis for its approved use in atopic dermatitis.

Seborrheic dermatitis shares a similar inflammatory pathophysiology with atopic dermatitis — it involves an exaggerated immune-inflammatory response to Malassezia yeast colonization combined with impaired skin barrier function. Because tacrolimus dampens this T-cell-mediated inflammatory cascade without causing the skin atrophy associated with long-term topical corticosteroid use, it is mechanistically well suited to chronic, relapsing facial dermatoses that require long-term maintenance therapy — exactly the profile of seborrheic dermatitis.

This is a clear "drug repurposing within dermatology" scenario: the drug is not being moved to an unrelated organ system, but extended from one chronic inflammatory facial dermatosis (atopic dermatitis) to a mechanistically related one (seborrheic dermatitis), which is reflected in the strength and volume of both clinical and observational evidence below.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02004860	Phase 3	Completed	120	Evaluated 0.1% tacrolimus ointment (Protopic®) as maintenance treatment for severe facial seborrheic dermatitis, aiming to reduce relapse frequency, prolong remission, and reduce topical steroid use
NCT01591070	Phase 4	Completed	104	Assessed proactive (once/twice weekly) 0.1% tacrolimus ointment use to maintain remission and reduce exacerbation incidence in adult facial seborrheic dermatitis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33010323	2021	RCT	J Am Acad Dermatol	Multicenter double-blind RCT comparing tacrolimus 0.1% vs. ciclopiroxolamine 1% for maintenance therapy in severe facial seborrheic dermatitis
22101215	2012	RCT	J Am Acad Dermatol	Single-blind RCT: hydrocortisone 1% ointment vs. tacrolimus 0.1% ointment for facial seborrheic dermatitis in adults
24171300	2013	Comparative trial	Ann Parasitol	Compared sertaconazole 2% cream vs. tacrolimus 0.03% cream efficacy in 60 seborrheic dermatitis patients
37067129	2023	Comparative trial	Indian J Dermatol Venereol Leprol	Oral itraconazole (2 days) plus topical tacrolimus vs. topical tacrolimus alone for maintenance treatment of seborrheic dermatitis (Vietnam)
26512166	2015	Cohort (Tier 1)	Ann Dermatol	Topical calcineurin inhibitor maintenance therapy with 0.1% tacrolimus ointment for facial seborrheic dermatitis
27804089	2017	Systematic Review (Tier 1)	Am J Clin Dermatol	Systematic review of topical treatments (antifungals, keratolytics, corticosteroids, calcineurin inhibitors) for facial seborrheic dermatitis
19222250	2009	Review	Am J Clin Dermatol	Review of topical calcineurin inhibitors' pathophysiology, safety, and efficacy in seborrheic dermatitis
12833030	2003	Open-label pilot study	J Am Acad Dermatol	18 patients treated with 0.1% tacrolimus for up to 28 days; 61% achieved complete clearance
39219446	2024	Systematic Review/NMA (Tier 1)	Clin Exp Allergy	Cochrane network meta-analysis of topical anti-inflammatory treatments for eczema, relevant to calcineurin inhibitor comparative efficacy/safety
19213227	2009	Review	J Drugs Dermatol	Overview of facial seborrheic dermatitis status and therapeutic horizons, including calcineurin inhibitors

Taiwan Market Information

Tacrolimus is currently not marketed in Taiwan (market_status: 未上市), and there are 0 registered authorizations. No product licenses, dosage form, or approved-indication records are available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information. (No structured warnings, contraindications, or drug-drug interaction data were available in the current evidence pack — this is tracked as data gap DG001, marked "Blocking" for safety pre-assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 is supported by a completed Phase 3 and a completed Phase 4 trial specifically designed for facial seborrheic dermatitis maintenance therapy, reinforced by 20 publications including multiple RCTs directly comparing tacrolimus to standard-of-care agents (hydrocortisone, ciclopiroxolamine, sertaconazole). The mechanistic rationale is also well established. However, the drug is not currently marketed in Taiwan and core safety documentation is missing, so guardrails are required before further action.

To proceed, the following is needed:

TFDA package insert / warnings and contraindications (DG001, Blocking — required before S1 safety pre-assessment can proceed)
Structured mechanism-of-action (MOA) data from DrugBank (DG002, High)
Regulatory pathway assessment for Taiwan market entry, given 0 current authorizations
Formal DDI query (current query status: not_found) to support safety review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.